Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2011

View Archived Issues

Pfizer describes identification of new drug for allergic rhinitis

VANTAGE 88 reveals activity of combination therapy for multiple myeloma

Biomarkers of kidney injury identified in patients with MM

Galectin Therapeutics reviews recent progress

AstraZeneca provides update on olaparib and TC-5214 programs

U.K. study uncovers new biomarker for bronchiolitis obliterans syndrome

Kissei presents new nonpurine adenosine A2A receptor antagonists

GSK begins phase IIa trial of GSK-2586881

DiaMedica's humanized MAb for type 2 diabetes shows improved binding affinity

Merck & Co. discloses new B-raf inhibitors

Novel GPR119 receptor agonists discovered in Japan

GlaxoSmithKline presents novel protein kinase inhibitors

New 11-beta-HSD1 inhibitors developed in Korea

Novel somatostatin sst5 receptor antagonists synthesized

ALS Therapy Development Institute collaborates with Biogen Idec and UCB

Topline phase III data presented on teriflunomide in MS

FDA issues update on Multaq review

Repligen completes acquisition

Clinuvel reports final data from phase III afamelanotide trial

Affibody and Nuclisome join forces to develop cancer therapeutics

TiGenix clear to begin phase I study of stem cell product

EMA validates MAA for single-tablet HIV-1 therapy

Galaczym obtains new orphan drug status

Salix Pharmaceuticals acquires Oceana Therapeutics

ImmunoGen and Lilly enter collaboration for antibody-based anticancer therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...